BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26552478)

  • 1. Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women.
    Tian Y; Wang C; Cheng L; Zhang A; Liu W; Guo L; Ye H; Huang Y; Chen J; Wen X; Xing Y; Zheng G; Sun Z; Li H; Zhang P; Liu W; Chen Y; Zhang Z; Xu Y; Huo Y; Ou Q
    J Ovarian Res; 2015 Nov; 8():72. PubMed ID: 26552478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors.
    Gasiorowska E; Kluz T; Lipski D; Warchoł W; Tykarski A; Nowak-Markwitz E
    Dis Markers; 2019; 2019():3890906. PubMed ID: 31583027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people.
    Cheng HY; Zeng L; Ye X; Ma RQ; Tang ZJ; Chu HL; Zhao YM; Zhu LR; Gao YN; Chang XH; Cui H
    Chin Med J (Engl); 2020 Jun; 133(11):1285-1291. PubMed ID: 32404690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human epididymis protein 4 reference intervals in a multiethnic asian women population.
    Mokhtar N; Thevarajah M; Ma N; M I
    Asian Pac J Cancer Prev; 2012; 13(12):6391-5. PubMed ID: 23464464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
    Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.
    Moore RG; Miller MC; Eklund EE; Lu KH; Bast RC; Lambert-Messerlian G
    Am J Obstet Gynecol; 2012 Apr; 206(4):349.e1-7. PubMed ID: 22301440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.
    Chang X; Ye X; Dong L; Cheng H; Cheng Y; Zhu L; Liao Q; Zhao Y; Tian L; Fu T; Chen J; Cui H
    Int J Gynecol Cancer; 2011 Jul; 21(5):852-8. PubMed ID: 21633297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
    Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
    Li W; Wang D
    Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: A multicenter prospective study.
    Shen F; Lu S; Peng Y; Yang F; Chen Y; Lin Y; Yang C; Wu L; Li H; Zheng Y
    Clin Chim Acta; 2017 Aug; 471():119-125. PubMed ID: 28549533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
    Zhang L; Chen Y; Wang K
    Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.
    Urban N; Thorpe J; Karlan BY; McIntosh MW; Palomares MR; Daly MB; Paley P; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2087-94. PubMed ID: 22962406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer.
    Park Y; Kim Y; Lee EY; Lee JH; Kim HS
    Int J Cancer; 2012 Mar; 130(5):1136-44. PubMed ID: 21484794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.